Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL E JONES

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1083611636
CMS profile
94620
Location
CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$337.52

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $337.52 11

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL E JONES

NPI 1083611636 · CMS profile ID 94620

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083611636?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083611636?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083611636?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1083611636?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $337.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $15.9911/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698347 CMS
Janssen Scientific Affairs, LLC $93.3410/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787667693 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.5210/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850038955 CMS
AbbVie Inc. $21.4708/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794991327 CMS
Nestle HealthCare Nutrition Inc. $18.4508/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820910851 CMS
AbbVie Inc. $13.5905/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794991323 CMS
Merck Sharp & Dohme Corporation $15.4505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848506751 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7104/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850421281 CMS
RedHill Biopharma Inc. $95.6502/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799926657 CMS
AbbVie Inc. $17.6001/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794991319 CMS
AbbVie Inc. $13.7501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794991315 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $217.85 9
PY2020 $129.84 7
PY2021 $337.52 11
PY2022 $257.93 9
PY2023 $258.68 17
PY2024 $310.01 9
PY2025 $392.84 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,950.60 133
PY2024 Principal investigator $457,323.22 237
PY2023 Principal investigator $533,333.42 238
PY2022 Principal investigator $150,301.11 166
PY2021 Principal investigator $55,731.60 19
PY2020 Principal investigator $143,151.70 114
PY2019 Principal investigator $258,588.69 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

133 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $1,239.00 12/19/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673847
Principal investigator 1 F. Hoffmann-La Roche AG $6,087.00 12/19/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673850
Principal investigator 1 Janssen Research & Development, LLC $218.80 12/17/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175221211
Principal investigator 1 Genentech, Inc. $1,239.00 11/25/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673928
Principal investigator 1 Genentech, Inc. $893.00 11/25/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673932
Principal investigator 1 Genentech, Inc. $863.00 11/14/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673923
Principal investigator 1 Genentech, Inc. $893.00 10/29/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673915
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 10/27/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221092
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221539
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 10/27/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221569
Principal investigator 1 Genentech, Inc. $893.00 10/16/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673919
Principal investigator 1 Genentech, Inc. $2,590.00 10/09/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673911
Principal investigator 1 Genentech, Inc. $893.00 10/03/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673905
Principal investigator 1 F. Hoffmann-La Roche AG $2,679.00 09/18/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673802
Principal investigator 1 F. Hoffmann-La Roche AG $2,004.00 09/12/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673795
Principal investigator 1 F. Hoffmann-La Roche AG $1,002.00 08/26/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673772
Principal investigator 1 F. Hoffmann-La Roche AG $1,097.00 08/14/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673838
Principal investigator 1 Genentech, Inc. $2,736.00 08/13/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211673893
Principal investigator 1 F. Hoffmann-La Roche AG $19,293.00 08/07/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673776
Principal investigator 1 F. Hoffmann-La Roche AG $43.00 08/07/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673824
Principal investigator 1 F. Hoffmann-La Roche AG $1,002.00 08/07/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673829
Principal investigator 1 F. Hoffmann-La Roche AG $4,000.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673781
Principal investigator 1 F. Hoffmann-La Roche AG $585.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673785
Principal investigator 1 F. Hoffmann-La Roche AG $9,354.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673788
Principal investigator 1 F. Hoffmann-La Roche AG $18,708.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673791
Principal investigator 1 F. Hoffmann-La Roche AG $4,156.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673798
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673806
Principal investigator 1 F. Hoffmann-La Roche AG $585.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673810
Principal investigator 1 F. Hoffmann-La Roche AG $20,000.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673814
Principal investigator 1 F. Hoffmann-La Roche AG $4,000.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673818
Principal investigator 1 F. Hoffmann-La Roche AG $2,680.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673827
Principal investigator 1 F. Hoffmann-La Roche AG $12,393.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673833
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 07/31/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673844
Principal investigator 1 Genentech, Inc. $653.00 07/30/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211673901
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 07/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221027
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 07/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221203
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 07/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221254
Principal investigator 1 F. Hoffmann-La Roche AG $2,171.00 07/22/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673779
Principal investigator 1 Janssen Research & Development, LLC $6,340.00 07/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175221370
Principal investigator 1 Genentech, Inc. $16,450.00 07/11/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211673897
Principal investigator 1 Genentech, Inc. $2,438.00 06/19/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673855
Principal investigator 1 Genentech, Inc. $683.00 06/12/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673876
Principal investigator 1 Genentech, Inc. $2,028.00 05/27/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673860
Principal investigator 1 Genentech, Inc. $2,288.00 05/27/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673889
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221050
Principal investigator 1 Janssen Research & Development, LLC $6,340.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221083
Principal investigator 1 Janssen Research & Development, LLC $6,340.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221107
Principal investigator 1 Janssen Research & Development, LLC $450.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221245
Principal investigator 1 Janssen Research & Development, LLC $450.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221314
Principal investigator 1 Janssen Research & Development, LLC $450.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221324
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 05/21/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221584
Principal investigator 1 Genentech, Inc. $2,257.00 05/08/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673867
Principal investigator 1 Genentech, Inc. $5,194.00 05/08/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211673880
Principal investigator 1 Janssen Research & Development, LLC $3,727.00 04/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220956
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221001
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 04/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221011
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221160
Principal investigator 1 Janssen Research & Development, LLC $6,340.00 04/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221260
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 04/28/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221510
Principal investigator 1 Genentech, Inc. $2,132.00 04/08/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673872
Principal investigator 1 ABBVIE INC. $184.40 03/27/2025 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202466972
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/25/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221042
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/25/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221299
Principal investigator 1 Janssen Research & Development, LLC $541.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220948
Principal investigator 1 Janssen Research & Development, LLC $541.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221022
Principal investigator 1 Janssen Research & Development, LLC $274.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221149
Principal investigator 1 Janssen Research & Development, LLC $541.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221173
Principal investigator 1 Janssen Research & Development, LLC $274.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221229
Principal investigator 1 Janssen Research & Development, LLC $274.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221281
Principal investigator 1 Janssen Research & Development, LLC $272.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221363
Principal investigator 1 Janssen Research & Development, LLC $274.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221386
Principal investigator 1 Janssen Research & Development, LLC $541.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221422
Principal investigator 1 Janssen Research & Development, LLC $541.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221461
Principal investigator 1 Janssen Research & Development, LLC $274.00 03/20/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221502
Principal investigator 1 Genentech, Inc. $4,894.00 03/19/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673852
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220907
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220920
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220928
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220938
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220965
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220972
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220985
Principal investigator 1 Janssen Research & Development, LLC $81.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175220991
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221035
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221061
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221068
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221075
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221100
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221116
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221123
Principal investigator 1 Janssen Research & Development, LLC $221.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221130
Principal investigator 1 Janssen Research & Development, LLC $221.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221136
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221143
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221168
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221180
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221194
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221220
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221238
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221269
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221276
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221288
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221306
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221333
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221339
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221348
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221356
Principal investigator 1 Janssen Research & Development, LLC $221.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221378
Principal investigator 1 Janssen Research & Development, LLC $221.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221393
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221400
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221407
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221414
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221429
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221436
Principal investigator 1 Janssen Research & Development, LLC $81.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221447
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221452
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221470
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221478
Principal investigator 1 Janssen Research & Development, LLC $221.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221487
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221495
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221521
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221531
Principal investigator 1 Janssen Research & Development, LLC $459.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221545
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221553
Principal investigator 1 Janssen Research & Development, LLC $242.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221562
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/13/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175221576
Principal investigator 1 ABBVIE INC. $760.40 03/06/2025 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202458573
Principal investigator 1 ABBVIE INC. $490.40 03/06/2025 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202458618
Principal investigator 1 Genentech, Inc. $20,000.00 02/25/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673864
Principal investigator 1 Genentech, Inc. $1,000.00 02/25/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211673884
Principal investigator 1 Genentech, Inc. $25,467.00 02/21/2025 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211673768
Principal investigator 1 ABBVIE INC. $8,417.20 02/05/2025 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202445598
Principal investigator 1 Janssen Research & Development, LLC $218.80 01/27/2025 Non-covered Recipient Entity
Tri State Gastroenterology Associates
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175221187
Principal investigator 1 ABBVIE INC. $973.60 01/02/2025 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202435607